Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077525 | 0.80 | MTNR1A (0.73) | MTNR1AALOX5CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL5225146 | 0.77 | MTNR1A (1.00) | MTNR1AALOX5MAPK1TP53KMT2A | |
| SCHEMBL7019321 | 0.75 | MTNR1A (0.80) | MTNR1AALOX5KMT2A | |
| SCHEMBL7204127 | 0.73 | MTNR1A (0.77) | MTNR1AALOX5 | |
| SCHEMBL6076183 | 0.72 | MAPK1 (0.33) | MTNR1AMAPK1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL7206601 | 0.68 | MTNR1A (0.56) | MTNR1ASMN1; SMN2MAPK1CYP3A4CYP2C19 | |
| SCHEMBL6075347 | 0.65 | MTNR1A (0.71) | MTNR1AALOX5TP53KMT2A | |
| SCHEMBL7199698 | 0.63 | MTNR1A (0.72) | MTNR1AALOX5 | |
| SCHEMBL6076446 | 0.61 | MTNR1A (0.44) | MTNR1ASMN1; SMN2CYP3A4CYP2C19TP53 | |
| SCHEMBL29196210 | 0.60 | HPGD (0.70) | SMN1; SMN2MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ALOX5 2867/4885SMN1; SMN2 4729/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ALOX5 2867/4885SMN1; SMN2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.